Literature DB >> 16686915

New appendix criteria open for a broader concept of chronic migraine.

J Olesen, M-G Bousser, H-C Diener, D Dodick, M First, P J Goadsby, H Göbel, M J A Lainez, J W Lance, R B Lipton, G Nappi, F Sakai, J Schoenen, S D Silberstein, T J Steiner.   

Abstract

After the introduction of chronic migraine and medication overuse headache as diagnostic entities in The International Classification of Headache Disorders, Second Edition, ICHD-2, it has been shown that very few patients fit into the diagnostic criteria for chronic migraine (CM). The system of being able to use CM and the medication overuse headache (MOH) diagnosis only after discontinuation of overuse has proven highly unpractical and new data have suggested a much more liberal use of these diagnoses. The International Headache Classification Committee has, therefore, worked out the more inclusive criteria for CM and MOH presented in this paper. These criteria are included in the appendix of ICHD-2 and are meant primarily for further scientific evaluation but may be used already now for inclusion into drug trials, etc. It is now recommended that the MOH diagnosis should no longer request improvement after discontinuation of medication overuse but should be given to patients if they have a primary headache plus ongoing medication overuse. The latter is defined as previously, i.e. 10 days or more of intake of triptans, ergot alkaloids mixed analgesics or opioids and 15 days or more of analgesics/NSAIDs or the combined use of more than one substance. If these new criteria for CM and MOH prove useful in future testing, the plan is to include them in a future revised version of ICHD-2.

Entities:  

Mesh:

Year:  2006        PMID: 16686915     DOI: 10.1111/j.1468-2982.2006.01172.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  228 in total

1.  [Botulinum toxin type A for preventive treatment of chronic migraines].

Authors:  H Göbel; A Heinze
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 2.  Cortical excitability in chronic migraine.

Authors:  Gianluca Coppola; Jean Schoenen
Journal:  Curr Pain Headache Rep       Date:  2012-02

3.  [Botulinum toxin type A in the prophylactic treatment of chronic migraine].

Authors:  H Göbel; A Heinze
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

Review 4.  Controversy over the classification of medication-overuse headache.

Authors:  Maurice B Vincent
Journal:  Curr Pain Headache Rep       Date:  2012-02

Review 5.  Medication overuse headache (MOH): complication of migraine or secondary headache?

Authors:  L Grazzi; G Bussone
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

6.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Authors:  L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti
Journal:  J Headache Pain       Date:  2012-05-29       Impact factor: 7.277

Review 7.  New prospects in the taxonomic classification of primary headaches.

Authors:  G C Manzoni; P Torelli
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

8.  SPARTACUS: underdiagnosis of chronic daily headache in primary care.

Authors:  G Giannini; V Favoni; S Bauleo; T Ferrante; G Pierangeli; F Albani; M L Bacchi Reggiani; A Baruzzi; P Cortelli; S Cevoli
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

9.  Agomelatine and migraine management: a successfully treated case series.

Authors:  Beatriz O Plasencia-García; Samuel L Romero-Guillena; Alicia Quirós-López; Sergio Ruiz-Doblado
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 10.  Medication overuse headache in children and adolescents.

Authors:  Matteo Chiappedi; Umberto Balottin
Journal:  Curr Pain Headache Rep       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.